Document:

bgne_Ex10_8

		
			Exhibit 10.8
		

		
			 
		

		
			CONSULTING AGREEMENT
		

		
			 
		

		
			THIS CONSULTING AGREEMENT (the “Consulting Agreement”), dated July 24, 2018, is entered into by BeiGene, Ltd., a Cayman Islands exempted company (the “Company”), and Xiaodong Wang (the “Consultant”).
		

		
			 
		

		
			WHEREAS, the Company desires to retain the services of the Consultant and the Consultant desires to perform certain services for the Company on a consulting basis; and 
		

		
			 
		

		
			WHEREAS, the Consultant is in the business of providing such services and has agreed to provide such services pursuant to the terms and conditions set forth in this Consulting Agreement;
		

		
			 
		

		
			NOW, THEREFORE in consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows:
		

		
			 
		

			
	
			
				 1.
			Services To Be Performed.  During the period starting on the date hereof (the “Effective Date”) and ending on December 31, 2020, unless terminated earlier in accordance with the provisions of Section 4 below (the “Consulting Period”), the Consultant agrees to perform consulting services as may be reasonably requested by the Company from time to time, including but not limited to (i) providing the Company with scientific knowledge and technique knowhow; (ii) helping to facilitate the Company’s relationship with the government, academic, investment, and medical community in China; (iii) assisting in the recruitment of potential employees to the Company, and (iv) facilitating business development with other pharmaceutical and biotech companies (collectively, the “Services”).  Consultant shall be expected to devote approximately ten (10) hours per workweek to the provision of Services hereunder and shall be expected to travel, as requested from time to time by the Company.  The Consultant agrees to keep the Company updated, promptly upon the Company’s request, of any progress, problems, and/or development of which the Consultant is aware regarding the Services.  The Company shall have the right to require such updates in writing from the Consultant.  The Consultant is responsible for providing the necessary equipment, tools, materials and supplies to perform the Services.

			
	
			
				 2.
			Independent Contractor Status.  It is the express intention of the parties to this Consulting Agreement that the Consultant is an independent contractor and not an employee, agent, joint venturer or partner of the Company for any purposes whatsoever.  The Consultant shall not be entitled to any benefits that the Company may make available to employees from time to time.  The Consultant shall be solely responsible for all appropriate and/or necessary income taxes, withholding taxes, payroll contributions, unemployment insurance and social security taxes and for maintaining adequate workers’ compensation insurance coverage for himself.  Consultant shall assume and accept all responsibilities that are imposed on independent contractors by any statute, regulation, rule of law, or otherwise.  Consultant is not the agent of Company and is not authorized and shall not have the power or authority to bind Company or incur any liability or obligation.  While Company is entitled to provide Consultant with general guidance to assist Consultant in completing the scope of work to Company’s satisfaction, Consultant is ultimately responsible for directing and controlling the performance of the task and the scope of work, in accordance with the terms and conditions of this Agreement.  Consultant shall use its best efforts, energy and skill in its own name and in such manner as it sees fit.  The Consultant retains the right to contract with other companies or entities for his services; provided, however, that such other engagements must not interfere with the Consultant’s performance of the Services or violate the provision of the Confidentiality, Non-Solicitation and Assignment of Inventions Agreement by and between Consultant and the Company.  Likewise, the Company retains a reciprocal right to contract with other companies and/or individuals for consulting services without restriction.

			
	
			
				 3.
			Consulting Fees.

			
	
			
				 (a)
			In exchange for the full, prompt, and satisfactory performance of all Services to be rendered to the Company hereunder during the Consulting Period, the Company shall provide the Consultant the following compensation (the “Compensation”): (i) a fixed fee of US$44,110 for the Services rendered hereunder 

		 

 

	during the period starting on the Effective Date and ending on December 31, 2018;  (ii) a fixed annual fee of US$100,000 for the Services rendered hereunder for the year ending December 31, 2019; (iii) a fixed annual fee of US$100,000 for the Services rendered hereunder for the year ending December 31, 2020; and (iv) and such additional compensation, which, if any, shall be determined in the sole discretion of the Company. The Compensation maybe amended from time to time by the mutual agreement of the Consultant and the Company, subject to the Company's compliance with any applicable legal or regulatory requirements or rules of any stock exchange on which its securities are listed from time to time.

			
	
			
				 (b)
			The Company will reimburse the Consultant for reasonable and necessary out-of-pocket expenses incurred by him in connection with the performance of the Services hereunder; provided that the Consultant promptly provides and maintains a detailed expense account and receipts for such expenses.  Additionally, any expenses in excess of $1,000 (aggregate per month) will need to be approved by the Company in writing prior to such cost being incurred.

			
	
			
				 4.
			Termination.

			
	
			
				 (a)
			The Company may, without prejudice to any right or remedy it may have due to any failure of the Consultant to perform his obligations under this Consulting Agreement, terminate the Consultation Period immediately upon thirty (30) days prior written notice to the Consultant.  In the event of termination, the Consultant shall, upon request, perform such work as may be requested to transfer work in process to the Company or to a party designated by the Company.

			
	
			
				 (b)
			In the event of termination, the Consultant shall be entitled to payment for Services performed and expenses paid or incurred prior to the effective date of termination.  Such payments shall constitute full settlement of any and all claims of the Consultant of every description against the Company.

			
	
			
				 (c)
			The Consultant expressly acknowledges that any termination of this Agreement will neither release nor discharge the Consultant from his obligations as specified in Sections 5,  7,  8 and 11 of this Agreement and his obligations under the attached Confidentiality, Non-Solicitation and Assignment of Inventions Agreement.

			
	
			
				 5.
			Restrictive Covenants.  As a condition of his engagement with the Company, the Consultant shall be required to execute, and hereby agrees to execute, the attached Confidentiality, Non-Solicitation and Assignment of Inventions Agreement (the “NDA”), which is attached hereto as Exhibit A.

			
	
			
				 6.
			Other Agreements.  The Consultant represents that his performance of all the terms of this Consulting Agreement and the performance of his duties as a consultant of the Company do not and will not breach any agreement with any third party to which the Consultant is a party (including without limitation any nondisclosure or non-competition agreement), and that the Consultant will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others, except for any confidential or proprietary information or material belonging to the Company which the Consultant used or accessed during his employment for the Company.

			
	
			
				 7.
			Return of Company Property.  Upon termination of this Consulting Agreement or at any other time upon request by the Company, the Consultant shall promptly deliver to the Company all records, files, memoranda, notes, designs, data, reports, price lists, customer lists, drawings, plans, computer programs, software, software documentation, sketches, laboratory and research notebooks and other documents (and all copies or reproductions of such materials) in his possession, custody or control relating in any way to the business or prospective business of the Company.

			
	
			
				 8.
			Cooperation.  The Consultant shall use his best efforts in the performance of his obligations under this Consulting Agreement.  The Company shall provide such access to its information and property as may be reasonably required in order to permit the Consultant to perform his obligations hereunder.  The Consultant shall cooperate with the Company’s personnel, shall not interfere with the conduct of the Company’s business and 

		 

 

	shall observe all rules, regulations and security requirements of the Company concerning the safety of persons and property.

			
	
			
				 9.
			Non-Assignability of Contract By Consultant.  This Consulting Agreement is personal to the Consultant and he shall not have the right to assign any of his rights or delegate any of his duties without the express written consent of the Company; provided, that in the event that the Consultant establishes a partnership, corporation or other entity, one purpose of which is to provide the Consulting Services, the consultant may assign this Consulting Agreement to such partnership, corporation or other business entity with the advance written consent of the Company.  Any non-consented-to assignment or delegation, whether express or implied or by operation of law, shall be void and shall constitute a breach and a default by the Consultant.

			
	
			
				 10.
			Assignment by the Company.  This Agreement shall be binding upon and inure to the benefit of the Company’s successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s assets or business.  Accordingly, this Agreement may be assigned by the Company to a person or entity which is an affiliate of the Company or a successor in interest to substantially all of the business operations of the Company.

			
	
			
				 11.
			Complete Agreement.  This Consulting Agreement contains the entire understanding between the parties and supersedes, replaces and takes precedence over any prior understanding or oral or written agreement between the parties respecting the subject matter of this Consulting Agreement.  There are no representations, agreements, arrangements, nor understandings, oral or written, between the parties relating to the subject matter of this Consulting Agreement that are not fully expressed herein.

			
	
			
				 12.
			Severability.  In the event any provision of this Consulting Agreement shall be held invalid, the same shall not invalidate or otherwise affect in any respect any other term or terms of this Consulting Agreement, which term or terms shall remain in full force and effect.

			
	
			
				 13.
			Non-Waiver.  No delay or omission by the Company in exercising any right under this Consulting Agreement shall operate as a waiver of that or any other right.  A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion.

			
	
			
				 14.
			Amendment.  This Consulting Agreement may be amended or modified only by a written instrument executed by both the Company and the Consultant.

			
	
			
				 15.
			Counterparts.  This Consulting Agreement may be executed in two (2) signed counterparts, each of which shall constitute an original, but all of which taken together shall constitute one and the same instrument.

			
	
			
				 16.
			Governing Law and Jurisdiction.  This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to conflicts of laws principles thereof.  The parties hereby consent to the jurisdiction of any state or federal court in the State of Delaware.  Accordingly, with respect to any such court action, the Employee hereby (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.

		
			[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
		

		
			

		 

 

IN WITNESS WHEREOF, the parties hereto have executed this Consulting Agreement as of the day and year set forth above.
		

			
					
						BEIGENE LTD.

					
					
						 

				
	
					
						By:  /s/ John V. Oyler
Name:  John V. Oyler
Title:  Chairman & CEO

					
					
						Date:  July 24, 2018

				
	
					
						XIAODONG WANG

					
					
						 

				
	
					
						/s/ Xiaodong Wang

					
					
						Date:  July 24, 2018

				

		
			 
		

		
			 
		

		
			 
		

		
			

		 

 

		

			 

		

		

		
			EXHIBIT A
		

		
			CONFIDENTIALITY, NON-SOLICITATION AND ASSIGNMENT OF INVENTIONS AGREEMENT
		

		
			BEIGENE LTD.
		

		
			July 24, 2018
		

		
			Xiaodong Wang
		

		
			Dear Xiaodong:
		

		
			This letter is to confirm our understanding with respect to (i) your agreement to protect and preserve information and property which is confidential and proprietary to BeiGene LTD. or any present or future parent, subsidiary or affiliate thereof (collectively, the “Company”), (ii) certain restrictions on competition and solicitation of employees or consultants of the Company, and (iii) your agreement with respect to the ownership of inventions, ideas, copyrights and patents which may be used in the business of the Company (the terms and conditions agreed to in this letter are hereinafter referred to as the “Agreement”).
		

		
			In consideration of and as a condition of the compensation and other benefits of my engagement by the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, we have agreed as follows:
		

			
	
			
				 1.
			Certain Acknowledgements and Agreements.

			
	
			
				 (i)
			We have discussed, and you recognize and acknowledge the competitive and proprietary aspects of the business of the Company.

			
	
			
				 (ii)
			You understand and acknowledge that the Company will be engaged in the research, development, manufacture, licensing or use of potential drugs directed against specific targets (such as genes, proteins, enzymes or other biological molecules) selected by the Company (“Company Targets”), including without limitation chemistry, pre-clinical studies, bio-marker discovery and clinical studies.  You acknowledge that the Company will be free to select Company Targets in its sole discretion, and that the business of the Company may change over the course of your engagement and that this Agreement shall remain in full force and effect and shall apply to the Company’s business and Company Targets as they exist at any time during your engagement.

			
	
			
				 (iii)
			You further acknowledge that, during the course of your performing services for the Company, the Company will furnish, disclose or make available to you Confidential Information (as defined below) related to the Company’s business.  You also acknowledge that such Confidential Information have been developed and will be developed by the Company through the expenditure by the Company of substantial time, effort and money and that all such Confidential Information could be used by you to compete with the Company.  You also acknowledge that if you become employed or affiliated with any competitor of the Company in violation of your obligations in this Agreement, it is inevitable that you would disclose the Confidential Information to such competitor and would use such Confidential Information, knowingly or unknowingly, on behalf of such competitor.  Further, in the course of your engagement, you will be introduced to customers and others with important relationships to the Company.  You acknowledge that any and all “goodwill” created through such introductions belongs exclusively to the Company, including, without limitation, any goodwill created as a result of direct or indirect contacts or relationships between you and any customers of the Company.

			
	
			
				 (iv)
			For purposes of this Agreement, “Confidential Information” means confidential and proprietary information of the Company, whether in written, oral, electronic or other form, including but not limited to, information and facts concerning business plans, customers, future customers, suppliers, licensors, licensees, partners, investors, affiliates or others, training methods and materials, financial information, sales prospects, client lists, inventions, or any scientific, technical or trade secrets of the Company or of any third party provided to you or the Company under a condition of confidentiality, provided that Confidential Information will not include information that is in the public domain other than through any fault or act by you.  The term “trade secrets,” as used in this Agreement, will be given its broadest possible interpretation and will include, without limitation, anything tangible or intangible or electronically kept or stored, which constitutes, represents, evidences or records or any secret scientific, technical, merchandising, production or management information, or any design, process, procedure, formula, invention, improvement or other confidential or proprietary information or documents.

		
			

		 

 

		

			 

		

		

			
	
			
				 2.
			Non-Competition.  During the Consulting Period (as defined in the Consulting Agreement by and between you and the Company) and for a period of one (1) year following the termination of the Consulting Period, regardless of the reason for such termination, you shall not, without the prior written consent of the Company, for yourself or on behalf of any other, either as principal, agent, stockholder, employee, consultant, representative or in any other capacity, directly or indirectly own, manage, operate or control, or be connected or employed by, or otherwise associate in any manner with, engage in or have a financial interest in any business anywhere in the world that is engaged in the research, development, manufacture, licensing or use of potential drugs directed against any Company Target, or in any other business in which you have any direct operating or scientific responsibility relating to the research, development, manufacture, licensing or use of potential drugs directed against any Company Target, except that nothing contained herein shall preclude you from:  (a) purchasing or owning stock in any such competitive business if such stock is publicly traded, and provided that your holdings do not exceed three percent (3%) of the issued and outstanding capital stock of such business, or (b) serving on the Board of Directors of a publicly traded company if your responsibilities do not include scientific input or direction relating to the research, development, manufacture, licensing or use of potential drugs directed against any Company Target.

			
	
			
				 3.
			Non-Solicitation.  During the Consulting Period (as defined in the Consulting Agreement by and between you and the Company) and for a period of eighteen (18) months following the termination of the Consulting Period, regardless of the reason for such termination, you will not, without the prior written consent of the Company:

			
	
			
				 (i)
			Either individually or on behalf of or through any third party, directly or indirectly, (A) solicit, entice or persuade or attempt to solicit, entice or persuade any employee of or consultant to the Company to leave the services of the Company or any parent, subsidiary or affiliate of the Company for any reason, or (B) employ, cause to be employed, or solicit the employment of any employee of or consultant to the Company while any such person is providing services to the Company or within six months after any such person ceases providing services to the Company; or 

			
	
			
				 (ii)
			Either individually or on behalf of or through any third party, directly or indirectly, interfere, with or attempt to interfere with, the relations between any employee of, or consultant to, the Company or any parent, subsidiary or affiliate the Company.

			
	
			
				 4.
			Reasonableness of Restrictions.  You further recognize and acknowledge that (i) the types of employment and activities which are prohibited by Section 2 and Section 3 are narrow and reasonable in relation to the skills which represent your principal salable asset both to the Company and to your other prospective employers and (ii) the specific but broad geographical scope of the provisions of Section 2 is reasonable, legitimate and fair to you in light of the global nature of research and development activities for the development of drugs and in light of the limited restrictions on the type of employment prohibited herein compared to the types of employment for which you are qualified to earn your livelihood.

			
	
			
				 5.
			Protected Information.  You will at all times, both during the period while you are performing services for the Company and after the termination of your provision of services to the Company for any reason or for no reason, maintain in confidence and will not, without the prior written consent of the Company, use, except in the course of performance of your duties for the Company or by court order, disclose or give to others any Confidential Information.  In the event you are questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive Confidential Information, in regard to any Confidential Information, or concerning any fact or circumstance relating thereto, you will promptly notify the Company.  Upon the termination of your provision of services to the Company for any reason or for no reason, or if the Company otherwise requests, (i) you will return to the Company all tangible Confidential Information and copies thereof (regardless how such Confidential Information or copies are maintained) and (ii) you will deliver to the Company any property of the Company which may be in your possession, including products, materials, memoranda, notes, records, reports, or other documents or photocopies of the same.  The terms of this Section 5 are in addition to, and not in lieu of, any statutory or other contractual or legal obligation that you may have relating to the protection of the Company’s Confidential Information.  The terms of this Section 5 will survive indefinitely any termination of your provision of services to the Company for any reason or for no reason.

		
			

		 

 

		

			 

		

		

			
	
			
				 6.
			Ownership of Ideas, Copyrights and Patents.

			
	
			
				 (a)
			Property of the Company.  All ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know-how, inventions, designs, developments, apparatus, techniques, methods, laboratory notebooks and formulae (collectively the “Inventions”) which may be used or useful in the business of the Company, whether patentable, copyrightable or not, which you may conceive, reduce to practice or develop during the period while you are performing services for the Company and for one (1) year thereafter, alone or in conjunction with another or others, whether during or out of regular business hours, whether or not on the Company’s premises or with the use of its equipment, and whether at the request or upon the suggestion of the Company or otherwise, will be the sole and exclusive property of the Company, and that you will not publish any of the Inventions without the prior written consent of the Company or its designee.  Without limiting the foregoing, you also acknowledge that all original works of authorship which are made by you (solely or jointly with others) within the scope of your engagement or which relate to the business of the Company or a Company affiliate and which are protectable by copyright are “works made for hire” pursuant to the United States Copyright Act (17 U.S.C. Section 101).  You hereby assign to the Company or its designee all of your right, title and interest in and to all of the foregoing.  You further represent that, to the best of your knowledge and belief, none of the Inventions will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or slander against or violate any other rights of any person, firm or corporation, and that you will use your best efforts to prevent any such violation.

			
	
			
				 (b)
			Cooperation.  At any time during or after the period during which you are performing services for the Company, you will fully cooperate with the Company and its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect the Company’s rights in and to any of such Inventions, including, but not limited to, joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights with respect to any such Inventions in the United States and in any and all other countries, provided that the Company will bear the expense of such proceedings, and that any patent or other legal right so issued to you personally will be assigned by you to the Company or its designee without charge by you.

			
	
			
				 (c)
			Licensing and Use of Innovations.  With respect to any Inventions, and work of any similar nature (from any source), whenever created, which you have not prepared or originated in the performance of your engagement, but which you provide to the Company or incorporate in any Company product or system, you hereby grant to the Company a royalty-free, fully paid-up, non-exclusive, perpetual and irrevocable license throughout the world to use, modify, create derivative works from, disclose, publish, translate, reproduce, deliver, perform, dispose of, and to authorize others so to do, all such Inventions.  You will not include in any Inventions you deliver to the Company or use on its behalf, without the prior written approval of the Company, any material which is or will be patented, copyrighted or trademarked by you or others unless you provide the Company with the written permission of the holder of any patent, copyright or trademark owner for the Company to use such material in a manner consistent with then-current Company policy.

			
	
			
				 (d)
			Prior Inventions.  Listed on Exhibit 4(d) to this Agreement are any and all Inventions in which you claim or intend to claim any right, title and interest (collectively, “Prior Inventions”), including, without limitation, patent, copyright and trademark interests, which to the best of your knowledge will be or may be delivered to the Company in the course of your engagement, or incorporated into any Company product or system.  You acknowledge that your obligation to disclose such information is ongoing during the period that you provide services to the Company.

			
	
			
				 (e)
			Prior Obligations.  The Company acknowledges that you have prior and ongoing obligations to the National Institute for Biological Sciences (“NIBS”).  Nothing in the Agreement shall conflict with, or is intended to conflict with, your obligations to NIBS.  To the extent that you believe your provisions of services to the Company creates a conflict with your obligations to NIBS, you agree to notify the Company and the parties will work in good faith toward a resolution of the conflict.

			
	
			
				 7.
			Disclosure to Future Employers.  You agree that you will provide, and that the Company, in its discretion, may similarly provide, a copy of the covenants contained in Sections 2,  3,  5 and 6 of this Agreement to 

		 

 

		

			 

		

	any business or enterprise which you may directly or indirectly own, manage, operate, finance, join, control or in which you may participate in the ownership, management, operation, financing, or control, or with which you may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise.

			
	
			
				 8.
			No Conflicting Agreements.  You hereby represent and warrant that you have no commitments or obligations inconsistent with this Agreement and you will indemnify and hold the Company harmless against loss, damage, liability or expense arising from any claim based upon circumstances alleged to be inconsistent with such representation and warranty.

			
	
			
				 9.
			Name & Likeness Rights.  You hereby authorize the Company to use, reuse, and to grant others the right to use and reuse, your name, photograph, likeness (including caricature), voice, and biographical information, and any reproduction or simulation thereof, in any form of media or technology now known or hereafter developed (including, but not limited to, film, video and digital or other electronic media), both during and after your engagement, for whatever purposes the Company deems necessary.

			
	
			
				 10.
			General.

			
	
			
				 (a)
			Notices.  All notices, requests, consents and other communications hereunder will be in writing, will be addressed to the receiving party’s address set forth above or to such other address as a party may designate by notice hereunder, and will be either (i) delivered by hand, (ii) sent by overnight courier, or (iii) sent by registered mail, return receipt requested, postage prepaid.  All notices, requests, consents and other communications hereunder will be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iii) if sent by registered mail, on the fifth business day following the day such mailing is made.

			
	
			
				 (b)
			Entire Agreement.  This Agreement and the Consulting Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof.  No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement will affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement.

			
	
			
				 (c)
			Modifications and Amendments.  The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto.

			
	
			
				 (d)
			Waivers and Consents.  The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions.  No such waiver or consent will be deemed to be or will constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar.  Each such waiver or consent will be effective only in the specific instance and for the purpose for which it was given, and will not constitute a continuing waiver or consent.

			
	
			
				 (e)
			Assignment.  The Company may assign its rights and obligations hereunder in connection with a merger or consolidation or to any person or entity that succeeds to all or substantially all of the Company’s business or that aspect of the Company’s business in which you are principally involved.  You may not assign your rights and obligations under this Agreement without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company will be void.

			
	
			
				 (f)
			Benefit.  All statements, representations, warranties, covenants and agreements in this Agreement will be binding on the parties hereto and will inure to the benefit of the respective successors and permitted assigns of each party hereto.  Nothing in this Agreement will be construed to create any rights or obligations except between the Company and you, and no person or entity other than the Company will be regarded as a third-party beneficiary of this Agreement.

		
			

		 

 

		

			 

		

		

			
	
			
				 (g)
			Governing Law.  This Agreement and the rights and obligations of the parties hereunder will be construed in accordance with and governed by the law of the State of Delaware, U.S., without giving effect to the conflict of law principles thereof.

			
	
			
				 (h)
			Jurisdiction, Venue and Service of Process.  Any legal action or proceeding with respect to this Agreement will be brought in the courts of Federal or State courts in the State of Delaware.  By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts.

			
	
			
				 (i)
			WAIVER OF JURY TRIAL.  ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT WILL BE RESOLVED BY A JUDGE ALONE AND EACH OF THE COMPANY AND YOU WAIVE ANY RIGHT TO A JURY TRIAL THEREOF.

			
	
			
				 (j)
			Severability.  The parties intend this Agreement to be enforced as written.  However, (i) if any portion or provision of this Agreement is to any extent declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected thereby, and each portion and provision of this Agreement will be valid and enforceable to the fullest extent permitted by law and (ii) if any provision, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby, the court making such determination will have the power to reduce the duration and/or geographic area of such provision, and/or to delete specific words and phrases (“blue-penciling”), and in its reduced or blue-penciled form such provision will then be enforceable and will be enforced.

			
	
			
				 (k)
			Headings and Captions.  The headings and captions of the various subdivisions of this Agreement are for convenience of reference only and will in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

			
	
			
				 (l)
			Injunctive Relief.  You hereby expressly acknowledge that any breach or threatened breach of any of the terms and/or conditions set forth in Section 2,  3,  5 or 6 of this Agreement will result in substantial, continuing and irreparable injury to the Company.  Therefore, in addition to any other remedy that may be available to the Company, the Company will be entitled to injunctive or other equitable relief by a court of appropriate jurisdiction in the event of any breach or threatened breach of the terms of Section 2,  3,  5 or 6 of this Agreement.

			
	
			
				 (m)
			No Waiver of Rights, Powers and Remedies.  No failure or delay by a party hereto in exercising any right, power or remedy under this Agreement, and no course of dealing between the parties hereto, will operate as a waiver of any such right, power or remedy of the party.  No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, will preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder.  The election of any remedy by a party hereto will not constitute a waiver of the right of such party to pursue other available remedies.  No notice to or demand on a party not expressly required under this Agreement will entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand.

			
	
			
				 (n)
			Counterparts.  This Agreement may be executed in two or more counterparts, and by different parties hereto on separate counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

			
	
			
				 (o)
			Opportunity to Review.  You hereby acknowledge that you have had adequate opportunity to review these terms and conditions and to reflect upon and consider the terms and conditions of this Agreement, and that you have had the opportunity to consult with counsel of your own choosing regarding such 

		 

 

		

			 

		

	terms.  You further acknowledge that you fully understand the terms of this Agreement and have voluntarily executed this Agreement.

			
	
			
				 (p)
			Survival of Acknowledgements and Agreements.  Your acknowledgements and agreements set forth in this Agreement will survive the termination of your provision of services to the Company for any reason or for no reason.

		
			[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
		

		
			

		 

 

		

			 

		

If the foregoing accurately sets forth our agreement, please so indicate by signing and returning to us the enclosed copy of this letter.
		

		
			Very truly yours, 
		

		
			BEIGENE LTD.
		

		
			By:  /s/ John V. Oyler
Name:  John  V. Oyler
Title:  Chairman & CEO
		

		
			Accepted and Approved:
		

			
					
						/s/ Xiaodong Wang
Print Name: Xiaodong Wang

					
					
						July 24, 2018
DateExhibit 10.1

 

AMENDMENT
No. 9 TO

SECOND AMENDED
AND RESTATED CREDIT AGREEMENT

 

THIS AMENDMENT NO. 9 TO
SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”), dated as of August 3, 2018, among ORCHIDS PAPER
PRODUCTS COMPANY, a Delaware corporation (“Borrower”), the Guarantors party hereto, the lenders party hereto
(“Lenders”) and U.S. BANK NATIONAL ASSOCIATION, as a Lender and as LC Issuer, Swing Line Lender and Administrative
Agent for the Lenders (in such capacity, “Administrative Agent”).

 

BACKGROUND

 

A.           Borrower,
Administrative Agent and Lenders are parties to that certain Second Amended and Restated Credit Agreement dated as of June 25,
2015 (as amended, supplemented and modified from time to time, the “Credit Agreement”).

 

B.           Borrower
has requested that Administrative Agent and Lenders amend the Credit Agreement as set forth herein.

 

C.           Administrative
Agent and Lenders are willing to amend the Credit Agreement upon the terms and conditions set forth below.

 

D.           NOW
THEREFORE, in consideration of the matters set forth in the recitals and the covenants and provisions herein set forth, and other
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

AGREEMENT

 

Section 1.             Definitions.
Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement.

 

Section 2.             Amendments
to the Credit Agreement. As of the Effective Date (as defined below), the Credit Agreement is hereby amended as follows:

 

(a)          Article
I of the Credit Agreement is hereby amended to add the following defined term:

 

“Eighth
Amendment” shall mean Amendment No. 8 to Second Amended and Restated Credit Agreement dated as of April 19, 2018 among
Borrower, Guarantors, Administrative Agent and Lenders.”

 

    	 	 	 

     

    

  

(b)          Upon
the date of this Agreement, the Applicable Margin and Applicable Fee Rate percentages in the Level IX Status column in the Pricing
Schedule for Eurocurrency Rate and Base Rate Advances and Commitment Fee shall each be increased by an additional one percent (1.0%)
in excess of the Applicable Margin and Applicable Fee Rate percentages in effect as of the date of this Agreement.

 

(c)          Section
6.1(j) of the Credit Agreement is hereby amended to provide that:

 

“(i) the
Cash-Flow Forecast for the period starting the week ending August 3, 2018 to and including October 31, 2018, tendered by Borrower
to and accepted by Administrative Agent prior to the Effective Date shall replace the Cash Flow Forecast in existence on the date
of this Agreement (“Existing Cash Flow Forecast”), but such Existing Cash Flow Forecast shall continue to be applicable
for purposes of measurement of compliance with the covenant set forth in Section 6.21(d) of the Credit Agreement to the extent
weekly periods covered thereby would be included in the rolling four week period for which compliance is measured, (ii) on or before
each of September 1, 2018 and October 1, 2018, Borrower shall provide to Administrative Agent an updated Cash-flow Forecast, which
in each case shall be acceptable to and approved by Administrative Agent in writing, it being understood and agreed, upon such
approval by Administrative Agent, such Cash-Flow Forecast shall be the Cash-Flow Forecast for purposes of measuring compliance
with the covenant set forth in Sections 6.21(d) and (f) of the Credit Agreement, (iii) on or before the third Business Day
of each week, Borrower shall provide to Administrative Agent (A) a line-by-line reconciliation of (1) the amounts of budgeted
expenditures and receipts for the immediately preceding week as set forth in the Cash-Flow Forecast most recently delivered to
and approved by Administrative Agent for such week and (2) the actual expenditures and receipts for such week (together with an
explanation, in reasonable detail, of any material differences between the budgeted and actual amounts) and (B) a certification
by the CSO, that such person has no reason to believe that such reconciliation is incorrect or misleading in any material respect,
and (iv) on or before the second Business Day of each week Borrower shall provide to Administrative Agent, a report on the
prior weekly sales by customer, together with a comparison to budgeted sales for such period and a certification by the CEO or
CSO that such person has no reason to believe that such reconciliation is incorrect or misleading in any material respect.”

 

(d)          Section
6.21(f) of the Credit Agreement is hereby deleted in its entirety and the following is inserted in substitution therefor:

 

“(f) Borrower
shall not permit total Net Cash Flow (as defined in the Cash-Flow Forecast) for any week in each rolling four week period covered
by the Cash Flow Forecast to be more than ten percent (10%) less than the projected Net Cash Flow as set forth in the Cash-Flow
Forecast for each such four week period.”

 

    	 	- 2 -	 

     

    

  

(e)          Notwithstanding
anything contained in the Credit Agreement to the contrary, payments of principal and interest due and payable on the Term Loans
and Draw Loans and payment of interest on the Revolving Loans otherwise due and payable on September 1, 2018 and October 1, 2018
or at the end of the applicable Interest Period if not falling on such dates, shall instead be due and payable on the earlier of
the occurrence of an Event of Default or October 31, 2018.

 

(f)           Notwithstanding
anything contained in the Credit Agreement to the contrary, Borrower agrees to, by not later than August 31, 2018, either provide
Administrative Agent with a signed purchase agreement in form and content acceptable to Administrative Agent for the purchase of
the equity or assets of Borrower in an amount sufficient to repay the outstanding Obligations in full or a fully executed firm
binding commitment from an institutional lender, in form and substance acceptable to Administrative Agent, for replacement financing
in an amount sufficient to repay all of Borrower’s Obligations to Administrative Agent and Lenders in full. By not later
than October 31, 2018, Borrower shall have closed on the sale of its equity or assets or refinancing and repaid the Obligations
in full.

 

Section 3.             Representations
and Warranties. To induce Administrative Agent and Lenders to execute this Agreement, Borrower hereby represents and warrants
to Administrative Agent and Lenders as follows:

 

(a)          Authorization;
No Conflict. Borrower is duly authorized to execute and deliver this Agreement. The execution, delivery and performance by
Borrowers of this Agreement, do not and will not (a) require any consent or approval of any governmental agency or authority (other
than any consent or approval which has been obtained and is in full force and effect), (b) conflict with (i) any provision of applicable
law, (ii) the charter, by-laws or other organizational documents of Borrower or (iii) any agreement, indenture, instrument or other
document, or any judgment, order or decree, which is binding upon Borrower or any of its properties or (c) require, or result in,
the creation or imposition of any Lien on any asset of Borrower or any other Loan Party (other than Liens in favor of Administrative
Agent created pursuant to the Loan Documents).

 

(b)          Binding
Effect. This Agreement constitutes the legal, valid and binding obligation of Borrower enforceable against Borrower in accordance
with its terms, subject to bankruptcy, insolvency and similar laws affecting the enforceability of creditors’ rights generally
and to general principles of equity (whether enforcement is sought by proceeding in equity or at law).

 

    	 	- 3 -	 

     

    

  

(c)          Continuation
of Representations and Warranties. After giving effect to this Agreement, each of the representations and warranties of Borrower
in the Credit Agreement and the other Loan Documents are true and correct in all material respects with the same effect as though
made on and as of the date hereof (except to the extent such representations and warranties expressly relate to a specific earlier
date, in which case such representations and warranties shall be true and correct in material respects as of such earlier date).

 

(d)          No
Event of Default. After giving effect to this Agreement, no Event of Default exists.

 

Section 4.             Conditions
Precedent. This Agreement shall be effective as of the date first set forth above, subject to the satisfaction of the following
conditions precedent (the date of such satisfaction being the “Effective Date”):

 

4.1          Execution
and Delivery. Borrower, Administrative Agent and Lenders shall have executed and delivered this Agreement.

 

4.2          No
Events of Default. No Event of Default under the Credit Agreement (other than the Existing Events of Default) shall have occurred
and be continuing or will result from the consummation of the transactions contemplated by this Agreement.

 

4.3          Representations
and Warranties. The representations and warranties set forth in Section 3 hereof are true and correct.

 

4.4          Organizational
Documents. Administrative Agent shall have received such customary documents and certificates as Administrative Agent may reasonably
request relating to the organization, existence and good standing of Borrower and the authorization of the transactions contemplated
by this Agreement.

 

4.5          Payment
of Fees and Attorney Costs. Borrower shall have paid to Administrative Agent all reasonable out-of-pocket costs and expenses
of Administrative Agent (including legal fees, auditor fees, and consultant fees) in connection with the negotiation, documentation
and closing of this Agreement.

 

    	 	- 4 -	 

     

    

  

Section 5.             Fees.
In consideration for Administrative Agent and Lenders entering into this Agreement, Borrower agrees to pay to Administrative Agent,
for the pro rata benefit of Lenders executing this Agreement, an amendment fee in the amount of $1,250,000 (the “Amendment
Commitment Fee”), which shall be non-refundable and fully earned on the Effective Date of this Agreement, and shall be
due and payable, along with the Amendment Fee (as defined in the Eighth Amendment) on the earliest of (i) October 31, 2018, (ii)
occurrence of an Event of Default, or (iii) sale of all or substantially all of Borrower’s Assets or equity interests or
refinancing of the Obligations, provided, that in the event Borrower repays the Obligations in full by October 31, 2018 and no
Event of Default exists, the Amendment Commitment Fee shall be reduced by $750,000 so that only $500,000 will be due on account
of such Amendment Commitment Fee hereunder. Any consulting or financing fees due to any Investment Banker with respect to this
Agreement shall not be paid prior to the payment in full of all Obligations owed to Administrative Agent and Lenders under the
Credit Agreement and the other Loan Documents.

 

Section 6.              Miscellaneous.

 

6.1          Effect
of Agreement. The execution, delivery and effectiveness of this Agreement shall not operate as a waiver of any right, power
or remedy of Administrative Agent or Lenders under the Credit Agreement or any other Loan Document, or constitute a waiver of any
provision of the Credit Agreement or any other Loan Document, except as specifically set forth herein, and Borrower and each Guarantor
hereby fully confirms, affirms and ratifies each Loan Document to which it is a party. Except as specifically modified hereby,
the Credit Agreement and the other Loan Documents remain in full force and effect.

 

6.2          Counterparts.
This Agreement may be executed in any number of counterparts and by the different parties on separate counterparts, and each such
counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.
Delivery of the executed counterpart of this Agreement by telecopy or electronic mail shall be as effective as delivery of a manually
executed counterpart to this Agreement.

 

6.3          Costs
and Expenses. Borrower shall pay all invoices of Administrative Agent’s auditors, financial consultants and any legal
counsel of Agent within five days of written request.

 

6.4          Severability.
The illegality or unenforceability of any provision of this Agreement or any instrument or agreement required hereunder shall not
in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any instrument or agreement
required hereunder.

 

6.5          Captions.
Section captions used in this Agreement are for convenience only, and shall not affect the construction of this Agreement.

 

    	 	- 5 -	 

     

    

  

6.6          Entire
Agreement. This Agreement embodies the entire agreement and understanding among the parties hereto and supersedes all prior
or contemporaneous agreements and understandings of such Persons, verbal or written, relating to the subject matter hereof.

 

6.7          References.
Any reference to the Credit Agreement contained in any notice, request, certificate, or other document executed concurrently with
or after the execution and delivery of this Agreement shall be deemed to include this Agreement unless the context shall otherwise
require. Reference in any of this Agreement, the Credit Agreement or any other Loan Document to the Credit Agreement shall be a
reference to the Credit Agreement as amended hereby and as further amended, modified, restated, supplemented or extended from time
to time.

 

6.8          Waiver
of Claims and Defenses. By execution of this Agreement, Borrower and each Guarantor acknowledges and confirms that it does
not have any offsets, defenses or claims arising out of or relating to this Agreement, the Credit Agreement or the other Loan Documents
against Administrative Agent, any Lender, or any of their subsidiaries, affiliates, officers, directors, employees, agents, attorneys,
predecessors, successors or assigns whether asserted or unasserted. The Borrower and Guarantors, for and on behalf of themselves
and their legal representatives, successors and assigns, do waive, release, relinquish and forever discharge the Administrative
Agent and each Lender, its parents, subsidiaries, and affiliates, its and their respective past, present and future directors,
officers, managers, agents, employees, insurers, attorneys, representatives and all of their respective heirs, successors and assigns
(collectively, the “Released Parties”), of and from any and all manner of action or causes of action, suits,
claims, demands, judgments, damages, levies and executions of whatsoever kind, nature or description arising on or before the date
hereof, including, without limitation, any claims, losses, costs or damages, including compensatory and punitive damages, in each
case whether known or unknown, asserted or unasserted, liquidated or unliquidated, fixed or contingent, direct or indirect, which
the Borrower or the Guarantors, or their legal representatives, successors or assigns, ever had or now have or may claim to have
against any of the Released Parties, with respect to any matter whatsoever, including, without limitation, the Loan Documents,
the administration of the Loan Documents, the negotiations relating to this Agreement and the other Loan Documents executed in
connection with this Agreement and any other instruments and agreements executed by the Borrower or any Guarantor in connection
with the Loan Documents or this Agreement, arising on or before the date hereof (collectively, “Claims”). 
The Borrower and each Guarantor acknowledges that they are aware that they may discover facts different from or in addition to
those they now know or believe to be true with respect to the Claims, and agree that the release contained in this Agreement is
and will remain in effect in all respects as a complete and general release as to all matters released in this Agreement, notwithstanding
any such different or additional facts.  The Borrower and each Guarantor agrees not to sue any Released Party or in any way
assist any other person or entity in suing a Released Party with respect to any claim released in this Section. Borrower and each
Guarantor acknowledges and agrees that Administrative Agent and the Lenders have fully and timely performed all of their respective
obligations and duties in compliance with the Loan Documents and applicable law, and has acted reasonably, in good faith, and appropriately
under the circumstances.

 

    	 	- 6 -	 

     

    

  

6.9          Governing
Law. THIS AGREEMENT SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF OKLAHOMA APPLICABLE TO
CONTRACTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES.

 

[signature page follows]

 

    	 	- 7 -	 

     

    

 

IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be duly executed and delivered by their duly authorized officers as of the date first
set forth above.

 

	 	BORROWER:
	 	 
	 	ORCHIDS PAPER PRODUCTS COMPANY

 

	 	By:	/s/ Jeffrey S. Schoen

	 	Name:	Jeffrey S. Schoen

	 	Title:	President and CEO

 

	 	GUARANTORS:
	 	 
	 	ORCHIDS MEXICO (DE) HOLDINGS, LLC

 

	 	By:	/s/ Jeffrey S. Schoen

	 	Name:	Jeffrey S. Schoen

	 	Title:	President and CEO

 

	 	ORCHIDS MEXICO (DE) MEMBER, LLC

 

	 	By:	/s/ Jeffrey S. Schoen

	 	Name:	Jeffrey S. Schoen

	 	Title:	President and CEO

 

	 	ORCHID PAPER PRODUCTS COMPANY OF SOUTH CAROLINA

 

	 	By:	/s/ Jeffrey S. Schoen

	 	Name:	Jeffrey S. Schoen

	 	Title:	President and CEO

 

	 	OPP ACQUISITION MEXICO, S. de. R.L.de C.V.

 

	 	By:	/s/ Jeffrey S. Schoen

	 	Name:	Jeffrey S. Schoen

	 	Title:	President and CEO

 

    	 	 	 

     

    

  

	 	ADMINISTRATIVE AGENT:

 

	 	U.S. BANK NATIONAL ASSOCIATION, as a Lender, LC Issuer, Swing Line Lender and Administrative Agent

 

	 	By:	/s/ Mike Warren

	 	Name:	Mike Warren

	 	Title:	Sr. V.P.

 

	 	LENDERS:

 

	 	JPMORGAN CHASE BANK, N.A., as a Lender

 

	 	By:	/s/ R. Alan Green

	 	Name:	R. Alan Green

	 	Title:	Authorized Officer

 

	 	SUNTRUST BANK, as a Lender

 

	 	By:	/s/ Samuel M. Ballesteros

	 	Name:	Samuel M. Ballesteros

	 	Title:	Senior Vice President

 

	 	FIRST TENNESSEE BANK, as a Lender

 

	 	By:	/s/ Jim Hennigan

	 	Name:	Jim Hennigan

	 	Title:	Senior Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]